{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:54:47Z","timestamp":1790801687061,"version":"4.1.0"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21572271"],"award-info":[{"award-number":["21572271"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejmech.2023.116120","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T08:36:14Z","timestamp":1704357374000},"page":"116120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms"],"prefix":"10.1016","volume":"265","author":[{"given":"Luyang","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanchun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfa","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.116120_bib1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1152\/physrev.00007.2018","article-title":"Structure, gating, and regulation of the CFTR anion channel","volume":"99","author":"Csan\u00e1dy","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2023.116120_bib2","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.116120_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","article-title":"Role of CFTR in epithelial physiology","volume":"74","author":"Saint-Criq","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2023.116120_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2017.02.024","article-title":"Molecular structure of the human CFTR ion channel","volume":"169","author":"Liu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.116120_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12950-017-0176-1","article-title":"Neutrophil extracellular traps and the dysfunctional innate immune response of cystic fibrosis lung disease: a review","volume":"14","author":"Law","year":"2017","journal-title":"J. Inflamm."},{"key":"10.1016\/j.ejmech.2023.116120_bib6","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CMR.15.2.194-222.2002","article-title":"Lung infections associated with cystic fibrosis","volume":"15","author":"Lyczak Jeffrey","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2023.116120_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2016.00275","article-title":"CFTR modulators: shedding light on precision medicine for cystic fibrosis","volume":"7","author":"Lopes-Pacheco","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116120_bib8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2021.09.042","article-title":"Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies","volume":"76","author":"Dana","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2023.116120_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib10","article-title":"Current development of CFTR potentiators in the last decade","volume":"204","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24055010","article-title":"Revisiting host-pathogen interactions in cystic fibrosis lungs in the era of CFTR modulators","volume":"24","author":"Ribeiro","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.116120_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26051275","article-title":"Evaluation of fused pyrrolothiazole systems as correctors of mutant CFTR protein","volume":"26","author":"Span\u00f2","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.116120_bib13","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1021\/acs.jmedchem.9b01416","article-title":"Multitarget CFTR modulators endowed with multiple beneficial side effects for cystic fibrosis patients: toward a simplified therapeutic approach","volume":"62","author":"Tassini","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcf.2019.10.021","article-title":"CFTR: new insights into structure and function and implications for modulation by small molecules","volume":"19","author":"Kleizen","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib15","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1073\/pnas.1815287115","article-title":"Molecular structure of the ATP-bound, phosphorylated human CFTR","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.116120_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2022.09.010","article-title":"Structure basis of CFTR folding, function and pharmacology","volume":"22","author":"Hwang","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00018-016-2387-7","article-title":"From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking","volume":"74","author":"Farinha","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2023.116120_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.molcel.2005.09.007","article-title":"Folding of CFTR is predominantly cotranslational","volume":"20","author":"Kleizen","year":"2005","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2023.116120_bib19","article-title":"Mechanisms of CFTR folding at the endoplasmic reticulum","volume":"3","author":"Sj","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116120_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.coph.2017.09.014","article-title":"Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis","volume":"34","author":"Mijnders","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116120_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cell.2011.11.023","article-title":"Requirements for efficient correction of \u0394F508 CFTR revealed by analyses of evolved sequences","volume":"148","author":"Mendoza","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.116120_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","author":"Fiedorczuk","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.116120_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037682","article-title":"A chaperone trap contributes to the onset of cystic fibrosis","volume":"7","author":"Coppinger","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.116120_bib24","doi-asserted-by":"crossref","first-page":"L719","DOI":"10.1152\/ajplung.00431.2015","article-title":"Trafficking and function of the cystic fibrosis transmembrane conductance regulator: a complex network of posttranslational modifications","volume":"311","author":"McClure","year":"2016","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.ejmech.2023.116120_bib25","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1083\/jcb.200312018","article-title":"Misfolding diverts CFTR from recycling to degradation","volume":"164","author":"Sharma","year":"2004","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.116120_bib26","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1191542","article-title":"Peripheral protein quality control removes unfolded CFTR from the plasma membrane","volume":"329","author":"Okiyoneda","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.116120_bib27","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib28","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.aaw7611","article-title":"Structural identification of a hotspot on CFTR for potentiation","volume":"364","author":"Liu","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.116120_bib29","doi-asserted-by":"crossref","first-page":"18843","DOI":"10.1073\/pnas.1105787108","article-title":"Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809","volume":"108","author":"Van Goor","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.116120_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cells11121868","article-title":"One size does not fit all: the past, present and future of CF causal therapies","volume":"11","author":"Ensinck","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2023.116120_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01100","article-title":"Peripheral protein quality control as a novel drug target for CFTR stabilizer","volume":"9","author":"Fukuda","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116120_bib32","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00080-2017","article-title":"Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codons","volume":"4","author":"Pranke","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ejmech.2023.116120_bib33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2472555217729790","article-title":"Use of a high-throughput phenotypic screening strategy to identify amplifiers, a novel pharmacological class of small molecules that exhibit functional synergy with potentiators and correctors","volume":"23","author":"Giuliano","year":"2018","journal-title":"SLAS Discov"},{"key":"10.1016\/j.ejmech.2023.116120_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54158-2","article-title":"Nanomolar-potency \u201cco-potentiator\u201d therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants","volume":"9","author":"Phuan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.116120_bib35","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.1995.268.4.C886","article-title":"cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein","author":"Illek","year":"1995","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejmech.2023.116120_bib36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1469-7793.2000.t01-1-00317.x","article-title":"Two mechanisms of genistein inhibition of cystic fibrosis transmembrane conductance regulator Cl\u2212 channels expressed in murine cell line","volume":"524","author":"Lansdell","year":"2000","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejmech.2023.116120_bib37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1085\/jgp.111.3.477","article-title":"Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating","volume":"111","author":"Wang","year":"1998","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.ejmech.2023.116120_bib38","doi-asserted-by":"crossref","first-page":"35079","DOI":"10.1074\/jbc.M303098200","article-title":"Nanomolar affinity small molecule correctors of defective \u03b4f508-CFTR chloride channel gating","volume":"278","author":"Yang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib39","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1124\/mol.105.010959","article-title":"Phenylglycine and sulfonamide correctors of defective \u0394F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating","volume":"67","author":"Pedemonte","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116120_bib40","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.116120_bib41","doi-asserted-by":"crossref","first-page":"9776","DOI":"10.1021\/jm5012808","article-title":"Discovery of N -(2,4-Di- tert -butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator","volume":"57","author":"Hadida","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib42","series-title":"Annu. Rep. Med. Chem.","first-page":"383","article-title":"Case history","author":"Hadida","year":"2014"},{"key":"10.1016\/j.ejmech.2023.116120_bib43","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201708-668PS","article-title":"The U.S. Food and drug administration's experience with ivacaftor in cystic fibrosis. Establishing efficacy using in vitro data in lieu of a clinical trial","volume":"15","author":"Durmowicz","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.ejmech.2023.116120_bib45","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib46","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2\u20135 years (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple CFTR channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102542","article-title":"Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator","volume":"24","author":"Laselva","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2023.116120_bib49","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/jpet.117.241497","article-title":"Altering metabolic profiles of drugs by precision deuteration 2: discovery of a deuterated analog of ivacaftor with differentiated pharmacokinetics for clinical development","volume":"362","author":"Harbeson","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.116120_bib50","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(16)30138-2","article-title":"WS13.6 CTP-656 tablet confirmed superiority of pharmacokinetic profile relative to Kalydeco \u00ae in Phase I clinical studies","volume":"15","author":"Uttamsineh","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01221","article-title":"Identification and characterization of novel CFTR potentiators","volume":"9","author":"Gees","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116120_bib52","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1021\/acs.jmedchem.7b01288","volume":"61","author":"Van Der Plas","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib53","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1021\/acs.jmedchem.0c01796","article-title":"Discovery of GLPG2451, a novel once daily potentiator for the treatment of cystic fibrosis","volume":"64","author":"Van Der Plas","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib54","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1085\/jgp.201912360","article-title":"Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770","volume":"151","author":"Yeh","year":"2019","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.ejmech.2023.116120_bib55","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1085\/jgp.201711886","article-title":"A common mechanism for CFTR potentiators","volume":"149","author":"Yeh","year":"2017","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.ejmech.2023.116120_bib56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jcf.2019.05.006","article-title":"GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: an open-label, single-arm, phase 2a study (SAPHIRA1)","volume":"18","author":"Davies","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib57","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S1569-1993(20)30226-5","article-title":"WS11.5 Evaluation of combinations of the CFTR potentiator dirocaftor, corrector posenacaftor and amplifier nesolicaftor in cystic fibrosis subjects with two copies of the F508del mutation","volume":"19","author":"Downey","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib58","first-page":"S17","article-title":"WS09.1 First results of the HIT-CF ex vivo organoid study show rescue of CFTR with ultra-rare mutations by a novel triple combination of CFTR modulators","volume":"20","author":"Silva","year":"2021","journal-title":"Abstr. 44th Eur. Cyst. Fibros. Conf. 2021"},{"key":"10.1016\/j.ejmech.2023.116120_bib59","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2147\/COPD.S257474","article-title":"Efficacy and safety of the CFTR potentiator icenticaftor (QBW251) in COPD: results from a phase 2 randomized trial","volume":"15","author":"Rowe","year":"2020","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.ejmech.2023.116120_bib60","doi-asserted-by":"crossref","first-page":"7241","DOI":"10.1021\/acs.jmedchem.1c00343","article-title":"Discovery of icenticaftor (QBW251), a cystic fibrosis transmembrane conductance regulator potentiator with clinical efficacy in cystic fibrosis and chronic obstructive pulmonary disease","volume":"64","author":"Le Grand","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib61","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jcf.2020.11.002","article-title":"Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)","volume":"20","author":"Kazani","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib62","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202303-0458OC","article-title":"Icenticaftor, a CFTR potentiator, in COPD: a multicenter, parallel-group, double-blind clinical trial","author":"Martinez","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib63","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202307-1175ED","article-title":"Icenticaftor, novel therapy for COPD: this glass is half full","author":"Rennard","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib64","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jcf.2018.05.010","article-title":"Combination potentiator (\u2018co-potentiator\u2019) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators","volume":"17","author":"Phuan","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib65","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1074\/jbc.M116.764720","article-title":"Correctors and potentiators rescue function of the truncated W1282x-cystic fibrosis transmembrane regulator (CFTR) translation product","volume":"292","author":"Haggie","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib66","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jcf.2019.12.009","article-title":"Towards next generation therapies for cystic fibrosis: folding, function and pharmacology of CFTR","volume":"19","author":"Bose","year":"2020","journal-title":"ECFS Cyst. Fibros. Res."},{"key":"10.1016\/j.ejmech.2023.116120_bib67","article-title":"1-BENZYLSPIRO[PIPERIDINE-4,1\u2019-PYRIDO[3,4-b]indole] \u201cco-potentiators\u201d for minimal function CFTR mutants","volume":"209","author":"Jung-Ho Son","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib68","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/bph.15709","article-title":"A small molecule CFTR potentiator restores ATP\u2010dependent channel gating to the cystic fibrosis mutant G551D\u2010CFTR","volume":"179","author":"Liu","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116120_bib69","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nchembio.1253","article-title":"Mechanism-based corrector combination restores \u0394F508-CFTR folding and function","volume":"9","author":"Okiyoneda","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.116120_bib70","doi-asserted-by":"crossref","first-page":"9882","DOI":"10.1021\/bi9004842","article-title":"Correctors enhance maturation of \u0394F508 CFTR by promoting interactions between the two halves of the molecule","volume":"48","author":"Loo","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.116120_bib71","doi-asserted-by":"crossref","first-page":"L1117","DOI":"10.1152\/ajplung.00169.2005","article-title":"Rescue of \u0394F508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules","volume":"290","author":"Van Goor","year":"2006","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.ejmech.2023.116120_bib72","doi-asserted-by":"crossref","first-page":"24714","DOI":"10.1074\/jbc.M111.239699","article-title":"Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant","volume":"286","author":"Yu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib73","doi-asserted-by":"crossref","first-page":"33247","DOI":"10.1074\/jbc.C700175200","article-title":"Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein","volume":"282","author":"Wang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib74","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.3390\/ijms20215463","article-title":"Unravelling the regions of mutant F508del-CFTR more susceptible to the action of four cystic fibrosis correctors","volume":"20","author":"Amico","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.116120_bib75","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1124\/mol.110.065862","article-title":"A chemical corrector modifies the channel function of F508del-CFTR","volume":"78","author":"Chiaw","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116120_bib76","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.chembiol.2013.06.004","article-title":"Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction","volume":"20","author":"Farinha","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.116120_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.166955","article-title":"Co-translational folding of the first transmembrane domain of ABC-transporter CFTR is supported by assembly with the first cytosolic domain","volume":"433","author":"Kleizen","year":"2021","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.116120_bib78","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1091\/mbc.e13-05-0240","article-title":"VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1","volume":"24","author":"Ren","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejmech.2023.116120_bib79","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3390\/cells9030754","article-title":"Phenotyping of rare CFTR mutations reveals distinct trafficking and functional defects","volume":"9","author":"Ensinck","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2023.116120_bib80","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s40265-016-0611-2","article-title":"Lumacaftor\/ivacaftor: a review in cystic fibrosis","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2023.116120_bib81","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1586\/ecp.12.39","article-title":"Induction of cytochrome P450 enzymes: a view on human in vivo findings","volume":"5","author":"Hukkanen","year":"2012","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116120_bib82","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1183\/09031936.00174014","article-title":"Cystic fibrosis bone disease: is the CFTR corrector C18 an option for therapy?","volume":"45","author":"Velard","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2023.116120_bib83","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.chembiol.2014.02.021","article-title":"VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface","volume":"21","author":"Eckford","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.116120_bib84","doi-asserted-by":"crossref","first-page":"15215","DOI":"10.1074\/jbc.M110.184267","article-title":"Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations","volume":"286","author":"Pedemonte","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib85","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1164\/rccm.201704-0717OC","article-title":"Tezacaftor\/Ivacaftor in Subjects with Cystic Fibrosis and F508del\/F508del-CFTR or F508del\/G551D-CFTR","volume":"197","author":"Donaldson","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib86","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib87","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2020.11.003","article-title":"A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor\/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation","volume":"20","author":"McKone","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib88","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.116120_bib89","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/children10030554","article-title":"Efficacy and safety of elexacaftor-tezacaftor-ivacaftor in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Kapouni","year":"2023","journal-title":"Children"},{"key":"10.1016\/j.ejmech.2023.116120_bib90","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib91","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1021\/acs.jmedchem.7b01339","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib92","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jcf.2019.04.014","article-title":"CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials","volume":"18","author":"Bell","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib93","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay9669","article-title":"Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel","volume":"6","author":"Pedemonte","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2023.116120_bib94","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejmech.2017.12.030","article-title":"Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools","volume":"144","author":"Liessi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib95","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3389\/fphar.2018.00719","article-title":"Molecular mechanism of action of trimethylangelicin derivatives as CFTR modulators","volume":"9","author":"Laselva","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116120_bib96","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejmech.2018.03.080","article-title":"Design, synthesis and biological evaluation of novel trimethylangelicin analogues targeting nuclear factor kB (NF-kB)","volume":"151","author":"Marzaro","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib97","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1172\/JCI24898","article-title":"Small-molecule correctors of defective \u0394F508-CFTR cellular processing identified by high-throughput screening","volume":"115","author":"Pedemonte","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2023.116120_bib98","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1091\/mbc.e08-09-0929","article-title":"Mechanisms for rescue of correctable folding defects in CFTR\u0394F508","volume":"20","author":"Grove","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejmech.2023.116120_bib99","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1021\/bi4008758","article-title":"Bithiazole correctors rescue CFTR mutants by two different mechanisms","volume":"52","author":"Loo","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.116120_bib100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejmech.2015.05.030","article-title":"Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis","volume":"99","author":"Pesce","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib101","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3390\/biom11101417","article-title":"NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: a Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis","volume":"11","author":"Brandas","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2023.116120_bib102","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jmb.2014.07.026","article-title":"Restoration of NBD1 thermal stability is necessary and sufficient to correct \u0394F508 CFTR folding and assembly","volume":"427","author":"He","year":"2015","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.116120_bib103","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41591-018-0200-x","article-title":"Structure-guided combination therapy to potently improve the function of mutant CFTRs","volume":"24","author":"Veit","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib104","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","article-title":"VX-659\u2013Tezacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Davies","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib105","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/17460441.2020.1750592","article-title":"The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis","volume":"15","author":"Guerra","year":"2020","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.116120_bib106","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445\u2013Tezacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib107","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib108","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejmech.2023.116120_bib109","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3390\/jpm11040301","article-title":"Phenotyping rare CFTR mutations reveal functional expression defects restored by TRIKAFTATM","volume":"11","author":"Laselva","year":"2021","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib110","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator","volume":"57","author":"Laselva","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2023.116120_bib111","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","volume":"20","author":"Veit","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib112","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.116120_bib113","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1038\/s41598-023-34440-0","article-title":"Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel","volume":"13","author":"Renda","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.116120_bib114","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0006-291X(02)02883-8","article-title":"Benzo(c)quinolizinium drugs inhibit degradation of \u0394F508-CFTR cytoplasmic domain","volume":"300","author":"Stratford","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2023.116120_bib115","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1242\/jcs.114.22.4073","article-title":"Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells","volume":"114","author":"Dormer","year":"2001","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2023.116120_bib116","doi-asserted-by":"crossref","first-page":"27415","DOI":"10.1074\/jbc.274.39.27415","article-title":"Development of substituted benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel","volume":"274","author":"Becq","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib117","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/emmm.201302699","article-title":"Discovery of novel potent \u0394F 508\u2010 CFTR correctors that target the nucleotide binding domain","volume":"5","author":"Odolczyk","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib118","doi-asserted-by":"crossref","first-page":"6842","DOI":"10.1038\/s41598-021-83240-x","article-title":"New insights into structure and function of bis-phosphinic acid derivatives and implications for CFTR modulation","volume":"11","author":"Bitam","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.116120_bib119","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29276-y","article-title":"A novel triple combination of pharmacological chaperones improves F508del-CFTR correction","volume":"8","author":"Carlile","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.116120_bib120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ardp.201500352","article-title":"Phenylhydrazones as correctors of a mutant cystic fibrosis transmembrane conductance regulator: phenylhydrazones as CFTR correctors","volume":"349","author":"Nieddu","year":"2016","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2023.116120_bib121","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.chembiol.2010.11.016","article-title":"Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR","volume":"18","author":"Sampson","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.116120_bib122","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3390\/cells11010136","article-title":"Rescue of mutant CFTR trafficking defect by the investigational compound MCG1516A","volume":"11","author":"Lopes-Pacheco","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2023.116120_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175396","article-title":"Identification of novel F508del-CFTR traffic correctors among triazole derivatives","volume":"938","author":"Bacalhau","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116120_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.890284","article-title":"Allicin facilitates airway surface liquid hydration by activation of CFTR","volume":"13","author":"Qiu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116120_bib125","doi-asserted-by":"crossref","first-page":"36639","DOI":"10.1074\/jbc.M112.393637","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner","volume":"287","author":"Eckford","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib126","article-title":"CFTR activator increases intestinal fluid secretion and normalizes stool output in a mouse model of constipation","volume":"2","author":"O","year":"2016","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2023.116120_bib127","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1021\/acs.jmedchem.6b01792","article-title":"Nanomolar-potency aminophenyl-1,3,5-triazine activators of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel for prosecretory therapy of dry eye diseases","volume":"60","author":"Lee","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib128","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.3390\/ijms23095206","article-title":"Novel CFTR activator cact-3 ameliorates ocular surface dysfunctions in scopolamine-induced dry eye mice","volume":"23","author":"Jeon","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.116120_bib129","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1021\/acs.jmedchem.2c01382","article-title":"Synthetic strategies for improving solubility: optimization of novel pyrazolo[1,5- a ]pyrimidine CFTR activator that ameliorates dry eye disease","volume":"66","author":"Kim","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nchembio.275","article-title":"Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis","volume":"6","author":"Hutt","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.116120_bib131","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1038\/s41598-022-08661-8","article-title":"The NSAID glafenine rescues class 2 CFTR mutants via cyclooxygenase 2 inhibition of the arachidonic acid pathway","volume":"12","author":"Carlile","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.116120_bib132","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00018-018-2896-7","article-title":"Proteomic interaction profiling reveals KIFC1 as a factor involved in early targeting of F508del-CFTR to degradation","volume":"75","author":"Canato","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2023.116120_bib133","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1038\/s41467-022-31206-6","article-title":"Macrocycle-stabilization of its interaction with 14-3-3 increases plasma membrane localization and activity of CFTR","volume":"13","author":"Stevers","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.116120_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128866","article-title":"Evaluation of aminopyrrolidine amide to improve chloride transport in CFTR-defective cells","volume":"72","author":"Huguet","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.116120_bib135","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.bbrc.2013.12.130","article-title":"S-nitrosothiols increases cystic fibrosis transmembrane regulator expression and maturation in the cell surface","volume":"443","author":"Zaman","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2023.116120_bib136","doi-asserted-by":"crossref","first-page":"L263","DOI":"10.1152\/ajplung.00269.2014","article-title":"Augmentation of CFTR maturation by S -nitrosoglutathione reductase","volume":"310","author":"Zaman","year":"2016","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.ejmech.2023.116120_bib137","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jcf.2017.01.009","article-title":"Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR","volume":"16","author":"Donaldson","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib138","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.chembiol.2018.04.010","article-title":"Pharmacological inhibition of the ubiquitin ligase RNF5 rescues F508del-CFTR in cystic fibrosis airway epithelia","volume":"25","author":"Sondo","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2023.116120_bib139","doi-asserted-by":"crossref","first-page":"9797","DOI":"10.1021\/acs.jmedchem.3c00608","article-title":"Innovative strategy toward mutant CFTR rescue in cystic fibrosis: design and synthesis of thiadiazole inhibitors of the E3 ligase RNF5","volume":"66","author":"Brusa","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115730","article-title":"Identification of \u03b1-Tocopherol succinate as an RFFL-substrate interaction inhibitor inducing peripheral CFTR stabilization and apoptosis","volume":"215","author":"Taniguchi","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.116120_bib141","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaa1580","article-title":"A molecular switch in the scaffold NHERF1 enables misfolded CFTR to evade the peripheral quality control checkpoint","volume":"8","author":"Loureiro","year":"2015","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2023.116120_bib142","doi-asserted-by":"crossref","first-page":"C107","DOI":"10.1152\/ajpcell.00296.2013","article-title":"VIP regulates CFTR membrane expression and function in Calu-3 cells by increasing its interaction with NHERF1 and P-ERM in a VPAC1-and PKC\u03b5-dependent manner","volume":"307","author":"Alshafie","year":"2014","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejmech.2023.116120_bib143","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1242\/jcs.185629","article-title":"EPAC1 activation by cAMP stabilizes CFTR at the membrane by promoting its interaction with NHERF1","volume":"129","author":"Lobo","year":"2016","journal-title":"J. Cell Sci."},{"issue":"9","key":"10.1016\/j.ejmech.2023.116120_bib144","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.15252\/emmm.201607137","article-title":"Orkambi\u00ae and amplifier co\u2010therapy improves function from a rare CFTR mutation in gene\u2010edited cells and patient tissue","volume":"9","author":"Molinski","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib145","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jcf.2020.02.006","article-title":"Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA","volume":"19","author":"Dukovski","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib146","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00109-002-0363-1","article-title":"Aminoglycoside suppression of a premature stop mutation in a Cftr\u2013\/\u2013 mouse carrying a human CFTR-G542X transgene","volume":"80","author":"Du","year":"2002","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib147","doi-asserted-by":"crossref","DOI":"10.1038\/nm0496-467","article-title":"Aminoglycoside antibiotics restore CFfR function by overcoming premature stop mutations","volume":"2","author":"Howard","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib148","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jcf.2013.02.007","article-title":"Tobramycin is a suppressor of premature termination codons","volume":"12","author":"Altamura","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib149","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00109-006-0045-5","article-title":"Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model","volume":"84","author":"Du","year":"2006","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib150","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1165\/rcmb.2013-0282OC","article-title":"Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor","volume":"50","author":"Xue","year":"2014","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.116120_bib151","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00109-011-0787-6","article-title":"Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54","volume":"89","author":"Rowe","year":"2011","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib152","doi-asserted-by":"crossref","first-page":"10630","DOI":"10.1021\/jm3012992","article-title":"Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations","volume":"55","author":"Kandasamy","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116120_bib153","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/13543784.2020.1828862","article-title":"ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease","volume":"29","author":"Kerem","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2023.116120_bib154","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2021.01.009","article-title":"Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids","volume":"20","author":"Crawford","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib155","doi-asserted-by":"crossref","first-page":"L756","DOI":"10.1152\/ajplung.00038.2023","article-title":"The synthetic aminoglycoside ELX-02 induces readthrough of G550X-CFTR producing superfunctional protein that can be further enhanced by CFTR modulators","volume":"324","author":"Chen","year":"2023","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.ejmech.2023.116120_bib156","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1096\/fba.2021-00043","article-title":"Sheep models of F508del and G542X cystic fibrosis mutations show cellular responses to human therapeutics","volume":"3","author":"Viotti Perisse","year":"2021","journal-title":"FASEB BioAdv."},{"key":"10.1016\/j.ejmech.2023.116120_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111972","article-title":"Comprehensive analysis of combinatorial pharmacological treatments to correct nonsense mutations in the CFTR gene","volume":"22","author":"Venturini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.116120_bib158","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2018.12.001","article-title":"Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells","volume":"18","author":"Valley","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib159","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007723","article-title":"Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis","volume":"14","author":"Sharma","year":"2018","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ejmech.2023.116120_bib160","article-title":"Synergy between readthrough and nonsense mediated decay inhibition in a murine model of cystic fibrosis nonsense mutations","volume":"22","author":"McHugh","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.116120_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e01963","article-title":"Caffeine boosts Ataluren's readthrough activity","volume":"5","author":"Lentini","year":"2019","journal-title":"Heliyon"},{"key":"10.1016\/j.ejmech.2023.116120_bib162","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1165\/rcmb.2018-0316OC","article-title":"Nonsense-mediated RNA decay pathway inhibition restores expression and function of W1282X CFTR","volume":"61","author":"Keenan","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejmech.2023.116120_bib163","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcf.2019.02.009","article-title":"Decreased mRNA and protein stability of W1282X limits response to modulator therapy","volume":"18","author":"Aksit","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib164","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcf.2021.09.020","article-title":"Functional restoration of CFTR nonsense mutations in intestinal organoids","volume":"21","author":"De Poel","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2023.116120_bib165","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2023.116120_bib166","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.0711795105","article-title":"PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR -G542X nonsense allele in a CF mouse model","volume":"105","author":"Du","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2023.116120_bib167","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2023.116120_bib168","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S2213-2600(14)70100-6","article-title":"Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"2","author":"Kerem","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2023.116120_bib169","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1038\/s41467-021-24575-x","article-title":"A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.116120_bib170","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.ymthe.2023.01.014","article-title":"Use of 2,6-diaminopurine as a potent suppressor of UGA premature stop codons in cystic fibrosis","volume":"31","author":"Leroy","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2023.116120_bib171","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15140-z","article-title":"2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations","volume":"11","author":"Trzaska","year":"2020","journal-title":"Nat. Commun."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423010875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423010875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T14:55:56Z","timestamp":1736866556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423010875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":171,"alternative-id":["S0223523423010875"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116120","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116120"}}